Patents by Inventor Fupeng Ma

Fupeng Ma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8431584
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: June 5, 2012
    Date of Patent: April 30, 2013
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators—842
    Patent number: 8377940
    Abstract: Compounds of Formula (I) wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 5, 2008
    Date of Patent: February 19, 2013
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators 842
    Patent number: 8377939
    Abstract: Compounds of Formula I: wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: February 19, 2013
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130012529
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 10, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130005753
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130005750
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20130005751
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: September 13, 2012
    Publication date: January 3, 2013
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMAN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
    Publication number: 20120245187
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
    Type: Application
    Filed: June 5, 2012
    Publication date: September 27, 2012
    Applicant: NOVARTIS AG
    Inventors: Gerald David ARTMANN, III, Jason Matthew ELLIOTT, Nan JI, Donglei LIU, Fupeng MA, Nello MAINOLFI, Erik MEREDITH, Karl MIRANDA, James J. POWERS, Chang RAO
  • Heterobicyclic carboxamides as inhibitors for kinases
    Patent number: 8242125
    Abstract: The invention relates to novel organic compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.
    Type: Grant
    Filed: December 7, 2009
    Date of Patent: August 14, 2012
    Assignee: Novartis AG
    Inventors: Gerald David Artman, III, Jason Matthew Elliott, Nan Ji, Donglei Liu, Fupeng Ma, Nello Mainolfi, Erik Meredith, Karl Miranda, James J. Powers, Chang Rao
  • Metabotropic glutamate-receptor-potentiating isoindolones
    Patent number: 8153638
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: April 10, 2012
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Substituted Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators
    Publication number: 20110166155
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: January 6, 2011
    Publication date: July 7, 2011
    Inventors: Bradford VAN WAGENEN, Radhakrishnan UKKIRAMAPANDIAN, Joshua CLAYTON, Ian EGLE, James R. EMPFIELD, Methvin ISAAC, Fupeng MA, Abdelmalik SLASSI, Gary STEELMAN, Rebecca URBANEK, Sally WALSH
  • Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7968570
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: August 12, 2005
    Date of Patent: June 28, 2011
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • AZA-Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - 613
    Publication number: 20110053953
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8 and n are defined in the specification, methods for using said compounds, methods for making said compounds and pharmaceutical compositions containing said compounds.
    Type: Application
    Filed: January 31, 2008
    Publication date: March 3, 2011
    Inventors: Abdelmalik Slassi, Methvin Isaac, Joshua Clayton, Ian Egle, Babu Joseph, Fupeng Ma
  • Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
    Patent number: 7868008
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: January 11, 2011
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Metabotropic Glutamate-Receptor-Potentiating Isoindolones
    Publication number: 20100317674
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: August 23, 2010
    Publication date: December 16, 2010
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Metabotropic Glutamate Receptor Oxadiazole Ligands and Their Use as Potentiators
    Publication number: 20100280082
    Abstract: Compounds of Formula (I) wherein R1, R2, R3 R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 5, 2008
    Publication date: November 4, 2010
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Oxadiazole Derivatives and Their Use as Metabotropic Glutamate Receptor Potentiators - 842
    Publication number: 20100267740
    Abstract: Compounds of Formula (I) wherein R1 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 5, 2008
    Publication date: October 21, 2010
    Applicant: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi
  • Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7816354
    Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: December 6, 2006
    Date of Patent: October 19, 2010
    Assignee: AstraZeneca AB
    Inventors: Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma, Babu Joseph, Joshua Clayton, Krzysztof Swierczek
  • Metabotropic glutamate-receptor-potentiating isoindolones
    Patent number: 7807706
    Abstract: Compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined in the description, processes for the preparing the compounds, new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Grant
    Filed: February 15, 2006
    Date of Patent: October 5, 2010
    Assignee: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators 841
    Patent number: 7799792
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4 and Q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Grant
    Filed: June 6, 2008
    Date of Patent: September 21, 2010
    Assignee: AstraZeneca AB
    Inventors: Joshua Clayton, Ian Egle, James Empfield, James Folmer, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi